Table 3.
Positive and negative HER2 and Survivin markers frequency rates
| HER2 positive | HER2 Negative | P-value | Survivin Positive | Survivin Negative | P-value | |
|---|---|---|---|---|---|---|
| Immunohistochemistry staining | 0.0610 | |||||
| 0 | 20 (23.8%) | |||||
| 1 | 20 (23.8%) | |||||
| 2 | 41 (48.8%) | |||||
| 3 | 3 (3.6%) | |||||
| Different tumor grades | 0.269 | 0.046 | ||||
| Papillary neoplasm of low- malignant potential | 4 (40%) | 6 (60%) | 2 (10%) | 8 (80%) | ||
| Low-grade papillary urothelial carcinoma | 15 (50%) | 15 (50%) | 0 | 30 (100%) | ||
| High-grade papillary urothelial carcinoma | 25 (56.8%) | 19 (43.3%) | 7 (15.9%) | 37 (84.1%) | ||
| Gender | 0.662 | 0.590 | ||||
| Male | 38 (50%) | 38 (50%) | 9 (11.8%) | 67 (88.2%) | ||
| Female | 6 (75%) | 2 (25%) | 0 | 8 (100%) | ||
| Muscle invasion | 0.662 | 0.727 | ||||
| + | 19 (48.7%) | 20 (51.3%) | 5 (12.8%) | 34 (87.2%) | ||
| - | 25 (55.6%) | 20 (44.4%) | 4 (8.9%) | 41 (91.1%) | ||
| Perineural invasion | 0.765 | 0.100 | ||||
| + | 6 (46.2%) | 7 (53.8%) | 1 (7.7%) | 12 (92.3%) | ||
| - | 38 (53.5%) | 33 (46.5%) | 8 (11.3%) | 63 (88.7%) | ||
| lymphatic invasion | 0.801 | 0.100 | ||||
| + | 10 (47.6%) | 11 (52.4%) | 2 (9.5%) | 19 (90.5%) | ||
| - | 34 (54%) | 29 (46%) | 7 (11.1%) | 56 (88.9%) | ||
| blood vessel invasion | 0.765 | 0.100 | ||||
| + | 6 (46.2%) | 7 (53.8%) | 1 (7.7%) | 12 (92.3%) | ||
| - | 38 (53.5%) | 33 (46.5%) | 8 (11.3%) | 63 (88.7%) | ||
| Multicentricity | 0.109 | 0.100 | ||||
| + | 6 (33.3%) | 12 (66.7%) | 2 (1.1%) | 16 (88.9%) | ||
| - | 38 (57.6%) | 28(42.4%) | 7 (10.6%) | 59 (89.4%) | ||
| In-situ component | 0.343 | 0.370 | ||||
| + | 1 (25%) | 3 (75%) | 1 (25%) | 3 (75%) | ||
| - | 43 (53.1%) | 37 (46.3%) | 8 (10%) | 72 (90%) |